184 related articles for article (PubMed ID: 24760004)
1. Frequent mutations in EGFR, KRAS and TP53 genes in human lung cancer tumors detected by ion torrent DNA sequencing.
Cai X; Sheng J; Tang C; Nandakumar V; Ye H; Ji H; Tang H; Qin Y; Guan H; Lou F; Zhang D; Sun H; Dong H; Zhang G; Liu Z; Dong Z; Guo B; Yan H; Yan C; Wang L; Su Z; Li Y; Jones L; Huang XF; Chen SY; Wu T; Lin H
PLoS One; 2014; 9(4):e95228. PubMed ID: 24760004
[TBL] [Abstract][Full Text] [Related]
2. PIK3CA and TP53 gene mutations in human breast cancer tumors frequently detected by ion torrent DNA sequencing.
Bai X; Zhang E; Ye H; Nandakumar V; Wang Z; Chen L; Tang C; Li J; Li H; Zhang W; Han W; Lou F; Zhang D; Sun H; Dong H; Zhang G; Liu Z; Dong Z; Guo B; Yan H; Yan C; Wang L; Su Z; Li Y; Jones L; Huang XF; Chen SY; Gao J
PLoS One; 2014; 9(6):e99306. PubMed ID: 24918944
[TBL] [Abstract][Full Text] [Related]
3. Analysis of EGFR, KRAS and P53 mutations in lung cancer using cells in the curette lavage fluid obtained by bronchoscopy.
Yamaguchi F; Kugawa S; Tateno H; Kokubu F; Fukuchi K
Lung Cancer; 2012 Dec; 78(3):201-6. PubMed ID: 23026641
[TBL] [Abstract][Full Text] [Related]
4. Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC).
Lim EH; Zhang SL; Li JL; Yap WS; Howe TC; Tan BP; Lee YS; Wong D; Khoo KL; Seto KY; Tan L; Agasthian T; Koong HN; Tam J; Tan C; Caleb M; Chang A; Ng A; Tan P
J Thorac Oncol; 2009 Jan; 4(1):12-21. PubMed ID: 19096301
[TBL] [Abstract][Full Text] [Related]
5. Screening for EGFR and KRAS mutations in non-small cell lung carcinomas using DNA extraction by hydrothermal pressure coupled with PCR-based direct sequencing.
Liu Y; Wu BQ; Zhong HH; Hui P; Fang WG
Int J Clin Exp Pathol; 2013; 6(9):1880-9. PubMed ID: 24040454
[TBL] [Abstract][Full Text] [Related]
6. Comparison of targeted next-generation sequencing (NGS) and real-time PCR in the detection of EGFR, KRAS, and BRAF mutations on formalin-fixed, paraffin-embedded tumor material of non-small cell lung carcinoma-superiority of NGS.
Tuononen K; Mäki-Nevala S; Sarhadi VK; Wirtanen A; Rönty M; Salmenkivi K; Andrews JM; Telaranta-Keerie AI; Hannula S; Lagström S; Ellonen P; Knuuttila A; Knuutila S
Genes Chromosomes Cancer; 2013 May; 52(5):503-11. PubMed ID: 23362162
[TBL] [Abstract][Full Text] [Related]
7. Mutations of EGFR or KRAS and expression of chemotherapy-related genes based on small biopsy samples in stage IIIB and IV inoperable non-small cell lung cancer.
Deng LL; Deng HB; Lu CL; Guo Y; Wang D; Yan CH; Lv X; Shao YX
J Cancer Res Clin Oncol; 2014 Dec; 140(12):2097-105. PubMed ID: 24994038
[TBL] [Abstract][Full Text] [Related]
8. PTEN mutations and relationship to EGFR, ERBB2, KRAS, and TP53 mutations in non-small cell lung cancers.
Jin G; Kim MJ; Jeon HS; Choi JE; Kim DS; Lee EB; Cha SI; Yoon GS; Kim CH; Jung TH; Park JY
Lung Cancer; 2010 Sep; 69(3):279-83. PubMed ID: 20018398
[TBL] [Abstract][Full Text] [Related]
9. High resolution melting analysis for rapid and sensitive EGFR and KRAS mutation detection in formalin fixed paraffin embedded biopsies.
Do H; Krypuy M; Mitchell PL; Fox SB; Dobrovic A
BMC Cancer; 2008 May; 8():142. PubMed ID: 18495026
[TBL] [Abstract][Full Text] [Related]
10. Coexistence of EGFR with KRAS, or BRAF, or PIK3CA somatic mutations in lung cancer: a comprehensive mutation profiling from 5125 Chinese cohorts.
Li S; Li L; Zhu Y; Huang C; Qin Y; Liu H; Ren-Heidenreich L; Shi B; Ren H; Chu X; Kang J; Wang W; Xu J; Tang K; Yang H; Zheng Y; He J; Yu G; Liang N
Br J Cancer; 2014 May; 110(11):2812-20. PubMed ID: 24743704
[TBL] [Abstract][Full Text] [Related]
11. EGFR and KRAS mutational profiling in fresh non-small cell lung cancer (NSCLC) cells.
Stella GM; Scabini R; Inghilleri S; Cemmi F; Corso S; Pozzi E; Morbini P; Valentini A; Dore R; Ferrari S; Luisetti M; Zorzetto M
J Cancer Res Clin Oncol; 2013 Aug; 139(8):1327-35. PubMed ID: 23644698
[TBL] [Abstract][Full Text] [Related]
12. Genetic mutation analysis of human gastric adenocarcinomas using ion torrent sequencing platform.
Xu Z; Huo X; Ye H; Tang C; Nandakumar V; Lou F; Zhang D; Dong H; Sun H; Jiang S; Zhang G; Liu Z; Dong Z; Guo B; He Y; Yan C; Wang L; Su Z; Li Y; Gu D; Zhang X; Wu X; Wei X; Hong L; Zhang Y; Yang J; Gong Y; Tang C; Jones L; Huang XF; Chen SY; Chen J
PLoS One; 2014; 9(7):e100442. PubMed ID: 25025766
[TBL] [Abstract][Full Text] [Related]
13. Smoking status and self-reported race affect the frequency of clinically relevant oncogenic alterations in non-small-cell lung cancers at a United States-based academic medical practice.
Yamaguchi N; Vanderlaan PA; Folch E; Boucher DH; Canepa HM; Kent MS; Gangadharan SP; Majid A; Kocher ON; Goldstein MA; Huberman MS; Costa DB
Lung Cancer; 2013 Oct; 82(1):31-7. PubMed ID: 23932486
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of TP53, KRAS and EGFR mutations in nonsmall cell lung cancer: the EUELC cohort.
Scoccianti C; Vesin A; Martel G; Olivier M; Brambilla E; Timsit JF; Tavecchio L; Brambilla C; Field JK; Hainaut P;
Eur Respir J; 2012 Jul; 40(1):177-84. PubMed ID: 22267755
[TBL] [Abstract][Full Text] [Related]
15. Spectrum of somatic EGFR, KRAS, BRAF, PTEN mutations and TTF-1 expression in Brazilian lung cancer patients.
Carneiro JG; Couto PG; Bastos-Rodrigues L; Bicalho MA; Vidigal PV; Vilhena A; Amaral NF; Bale AE; Friedman E; De Marco L
Genet Res (Camb); 2014; 96():e002. PubMed ID: 24594201
[TBL] [Abstract][Full Text] [Related]
16. [Relationship between EGFR and KRAS mutations and prognosis in Chinese patients with non-small cell lung cancer: a mutation analysis with real-time polymerase chain reaction using scorpion amplification refractory mutation system].
Gao J; Chen JQ; Zhang L; Liang ZY
Zhonghua Bing Li Xue Za Zhi; 2012 Oct; 41(10):652-6. PubMed ID: 23302304
[TBL] [Abstract][Full Text] [Related]
17. Low frequency KRAS mutations in colorectal cancer patients and the presence of multiple mutations in oncogenic drivers in non-small cell lung cancer patients.
Jiang L; Huang J; Morehouse C; Zhu W; Korolevich S; Sui D; Ge X; Lehmann K; Liu Z; Kiefer C; Czapiga M; Su X; Brohawn P; Gu Y; Higgs BW; Yao Y
Cancer Genet; 2013; 206(9-10):330-9. PubMed ID: 24200637
[TBL] [Abstract][Full Text] [Related]
18. Genetic and epigenetic analysis of erbB signaling pathway genes in lung cancer.
Hoque MO; Brait M; Rosenbaum E; Poeta ML; Pal P; Begum S; Dasgupta S; Carvalho AL; Ahrendt SA; Westra WH; Sidransky D
J Thorac Oncol; 2010 Dec; 5(12):1887-93. PubMed ID: 21102258
[TBL] [Abstract][Full Text] [Related]
19. COLD-PCR enrichment of rare cancer mutations prior to targeted amplicon resequencing.
Milbury CA; Correll M; Quackenbush J; Rubio R; Makrigiorgos GM
Clin Chem; 2012 Mar; 58(3):580-9. PubMed ID: 22194627
[TBL] [Abstract][Full Text] [Related]
20. Comparison of next-generation sequencing and mutation-specific platforms in clinical practice.
Hinrichs JW; van Blokland WT; Moons MJ; Radersma RD; Radersma-van Loon JH; de Voijs CM; Rappel SB; Koudijs MJ; Besselink NJ; Willems SM; de Weger RA
Am J Clin Pathol; 2015 Apr; 143(4):573-8. PubMed ID: 25780010
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
